Non-amyloid–based drugs in clinical development for Alzheimer’s disease.
| Drug(s) | Company | Mechanism |
|---|---|---|
| ABT-089, ABT-560 | Abbott | Cholinergic |
| AC-1202 (Ketasyn) | Accera | Mitochondria |
| AL-108 | Allon Therapeutics | Microtubule |
| AQW051 | Novartis | undisclosed |
| AVE-1625 | Sanofi-Aventis | Cannabinoid |
| AVE-8122 | Sanofi-Aventis | undisclosed |
| AZD-1080 | AstraZeneca | GSK inhibitor |
| AZD-3480 (Ispronicline) | AZ / Targacept | Cholinergic |
| AZD-3480 | AstraZeneca | Cholinergic |
| BF2649 | Bioprojet/Ferrer | Histamine |
| CX-717 | Cortex | Glutamate |
| Dimebon | Medivation | Glutamate/Cholinergic |
| EHT-0202 | ExonHit Therapeutics | Anti-inflammatory |
| EVT-101 | Evotec | Glutamate |
| FGL-L | Enkam | NCAM mimetic |
| GT-1061 | Queens Univ | NO mimetic |
| GTS-21 | CoMentis | Cholinergic |
| GW189254, 239512, | GlaxoSmithKline | Histamine |
| HF0220 | HunterFleming | Anti-inflammatory |
| HT-0712 | Helicon | Anti-inflammatory |
| JNJ-17216498 | J&J | Histamine |
| Ladostigil | Technion | Cholinergic/MAO |
| Lecozotan | Wyeth | 5-HT |
| Leuprolide | Voyager | Cell cycle |
| LX6171 | Lexicon | undisclosed |
| MEM-1003 | Memory | Ca channel |
| MEM-3454 | Memory/Roche | Cholinergic |
| NGX-267 | TorreyPines | Cholinergic |
| NP-031112 | Neuropharma | GSK inhibitor |
| PRX-03140 | Epix / GSK | 5-HT |
| PRX-07034/37 | Epix | 5-HT |
| PYM-50028 | Phytopharm | Neurotrophic |
| Rosiglitazone | GlaxoSmithKline | PPAR |
| SAM315 | Wyeth | 5-HT |
| SAM531 | Wyeth | undisclosed |
| SGS-518 | Saegis/ Lundbeck | 5-HT |
| SGS-742 | Saegis | GABA |
| SR180711 | Sanofi-Aventis | Cholinergic |
| SR-57667 (Paliproden) | Sanofi-Aventis | Neurotrophic |
| SRA444 | Wyeth | 5-HT |
| SYN-114 | Synosia | 5-HT |
| T-817 | Toyama | Neurotrophic |
| TTP488 | TransTech/Pfizer | Rage |
| VP-025 | Vasogen | Anti-inflammatory |
| Xaliproden | Sanofi-Aventis | Neurotrophic |